The abnormal increase in CDK14 levels in prostate cancer is linked to METTL1-mediated modification of its mRNA expression in an m7G manner, resulting in enhanced CDK14 mRNA stability (Zhang et al., 2023c). This evidence concerns the gene CDK14 and prostate cancer.